Диссертация (1140095), страница 12
Текст из файла (страница 12)
Simioni, AR. Lazzaro, I.Cordiano // ThrombHaemost.- 1989.- Vol. 61(1).- P. 144-7.57.Green, David. Risk of future arterial cardiovascular events in patientswith idiopathic venous thromboembolism. / David Green// ASH Education BookJanuary 1.- 2009.- vol. 2009 no. 1.-P. 259-266.58.Gunen, H. Venous thromboemboli and exacerbations of COPD. /H.Gunen, G. Gulbas, In E [et al.]// Eur Respir J.- 2010.-Vol.
35.- P.1243–1248.59.Hamsten, A. Plasminogen activator inhibitor in plasma - risk factor forrecurrent myocardial infarction. /A. Hamsten, U. Defaire, G. Walldius [et al.]//Lancet.- 1987.-Vol 2(8549).- P.3–8.60.Hamsten, A. Increased plasma levels of a rapid inhibitor of tissueplasminogen activator in young survivors of myocardial infraction. / A.Hamsten,B.Wiman, U.Defaire, M. Blomback //N Engl J Med.- 1985.- Vol.
313(25).- P.1557–63.61.Heit, JA . Thrombophilia: common questions on laboratoryassessment and management". /JA.Heit //Hematology Am. Soc. Hematol. Educ.Program.- 2007.-Vol (1).-P. 127–35.62.Hoffstedt, J. The common -6754G/5G polymorphism in theplasminogen activator inhibitor-1 gene is strongly associated with obesity./J.Hoffstedt, I.L.Andersson, L.Persson [et al.]// Diabetologia.- 2002.-Vol.
45.-P.584–587.8863.J Am Coll Cardiol. Prognostic value of plasma fibrinolysis activationmarkers in cardiovascular disease. J Am Coll Cardiol.- 2010.- Vol. 55(24). P. 27019.64.Janzon, L. Smoking and fibrinolysis./ L. Janzon, IM. Nilsson//Circulation.- 1975.- Vol. 51. P. 1120-3.65.Jarnell, J. Association of European population levels of thromboticand inflammatory factors with risk of coronary heart disease: the MONICA OptionalHaemostasis Study / J.Jarnell, E.McCrum, A.Rumley [et al.]// Eur. Heart. J.- 2005.— Vol. 26, N 4. — P. 332-342.66.Jorgenson, E. Plasminogen activator inhibitor type-1 (PAI-1)polymorphism 4G/5G is associated with prostate cancer among men with a positivefamily history.
/ E.Jorgenson, S.R.Deitcher, M.Cicek [et al.]// Prostate.- 2007.-Vol.67.-P. 172-177.67.Juhan-Vague, I. Fibrinolytic factors and the risk of myocardialinfarction or sudden death in patients with angina pectoris. / I Juhan-Vague, SDMPyke, MC Alessi [et al.]// Circulation.- 1996.-Vol. 94(9).- P.
2057–63.68.Juhan-Vague, I. Deficient t-PA release and elevated PA inhibitorlevels in patientswith spontaneous or recurrent deep venous thrombosis. / I JuhanVague, J Valadier, MC Alessi [et al.]// Thromb Haemost.- 1987.- Vol. 57(1).-P. 67–72.69.Kahn, SR. Prevention of VTE in nonsurgical patients: AntithromboticTherapy and Prevention of Thrombosis, 9th ed: American College of ChestPhysicians Evidence-Based Clinical Practice Guidelines./ SR Kahn, W Lim, ASDunn [et al.]// Chest.- 2012.-Vol. 141(2 Suppl).- P. e195S-226S.70.Kaplan, K.L., et al., Blood. 53, 604 (1979).8971.Kearon, C.
An Evaluation of D-dimer in the Diagnosis of PulmonaryEmbolism. / C.Kearon, J.S.Ginsberg, J.Douketis[et al.]// Annals of IntrnalMedicine.- 2006.- Vol. 144: 11.-P. 812-821.72.Kim, RJ. Association between factor V Leiden, prothrombinG20210A, and methylenetetrahydrofolate reductase C677T mutations and events ofthe arterial circulatory system: a meta-analysis of published studies./ RJ Kim, RCBecker/ Am Heart J.- 2003.-Vol.
146.-P. 948–957.73.Konstantinides, S. Do PAI-1 and vitronectin promote or inhibitneointima formation? The exact role of the fibrinolytic system in vascularremodeling remains uncertain. / S Konstantinides, K Schafer, DJ Loskutoff//Arterioscler Thromb Vasc Biol.- 2002.-Vol 22(12).-P. 1943–5.74.Koster, T.Protein C deficiency in a controlled series of unselectedoutpatients: an infrequent but clear risk factor for venous thrombosis (LeidenThrombophilia Study) / T Koster, FR Rosendaal, E Briët [et al.]// Blood.- 1995.Vol. 85(10).-P. 2756-61.75.Kruithof, EKO. Plasminogen activator inhibitor-1 – development of aradioimmunoassay and observations on its plasma concentration during venousocclusion and after platelet aggregation.
/ EKO Kruithof, G. Nicolosa, F. Bachmann// Blood.- 1987.- Vol 70(5).- P. 1645–53.76.Laghrissi-Thode, F. Elevated platelet factor 4 and β-thromboglobulinplasma levels in depressed patients with ischemic heart disease. / F Laghrissi-Thode,WR Wagner, PC Pollock, MS Finkel// Biol Psychiatry.- 1997.-Vol 42.- P. 290-295.77.Lane, D.A. Inherited thrombophilia. Part I / D.A.Lane, P.M.Mannucci,K.A. Bauer [et al.]// Thromb Haemost.- 1996.- Vol.
76. P. 651–662.78.Lee, V.L. The relationship of soluble fibrin and cross-linked fibrindegradation products to the clinical cours of myocardial infarction. / V.L.Lee,90G.A.Ewald, C.R.McKenzie [et al.]// Arterioscler. Thromb. Vasc. Biol.- 1997.-Vol.17.-P. 628-633.79.Lekka, А. Correlation of coagulation markers, platelet parameters andrespiratory indexes in patients with chronic obstructive pulmonary disease.
/А.Lekka, M.Dalamaga, M. Triantafilli [et al.]//Haematologica.- 2008.- Vol.93(s1).- P. 409.- Abs.103.180.Lijun, Miao. Blood Gas Analysis and Plasma D-dimer levelsrelationship in Chronic Obstructive Pulmonary Disease Patients. / Miao Lijun,Zhang Ruixia, Sun Zhentao [et al.]// Life Sci J.- 2013.-Vol. 10(2).-P. 1668-1670.81.Liu, R.M. Oxidative stress, plasminogen activator inhibitor 1, and lungfibrosis. / R.M.Liu // Antioxid.
Redox. Signal.- 2008.-Vol. 10.- P. 303–319.82.Llach, F. Hypercoagulability, renal vein thrombosis and otherthrombotic complications of nephrоtic syndrome. / F. Llach// Kidney Int.- 1985.Vol. 28.- P. 429–435.83.Loskutoff, D.J. Structure of the human plasminogen activatorinhibitor-1 gene: non-random distribution of introns. / D.J. Loskutoff [et al.]//Biochemistry.- 1987.- Vol. 26.- P. 3763–3768.84.Lundgren, C.H. Elaboration of type-1 plasminogen activator inhibitorfrom adipocytes. A potential pathogenetic link between obesity and cardiovasculardisease. / C.H.Lundgren, S.L.Brown, T.K.
Nordt [et al.]// Circulation.- 1996.- Vol.93.- P. 106–110.85.Lupu, F. Localization and production of plasminogen activatorinhibitor-1 in human healthy and atherosclerotic arteries. / F Lupu, GE Bergonzelli,DA Heim [et al.] // Arterioscler Thromb.- 1993.- Vol. 13(7).-P. 1090–100.86.Mathers, CD. Projections of global mortality and burden of diseasefrom 2002 to 2030.
/ CD Mathers, D. Loncar// PLoS Med.- 2006.- Vol. 3.- P.442.9187.Meltzer, ME. Venous thrombosis risk associated with plasmahypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. / MEMeltzer, T Lisman, PG de Groot [et al.]// Blood.- 2010.- Vol. 116(4).- P. 113–21.88.Moreno, P.R. Atherothrombosis: the global approach for a globaldisease. Pathophysiology of atherothrombosis./ P.R.
Moreno// Highlightsmonograph from an International expert meeting on atherombosis. – Milan, 1998. –P. 25.89.Nachman, R.L. Hypercoagulable states./ R.L.Nachman, R.Silverstein//Ann.Intern. Med.- 1993.- Vol. 119.- P. 819–827.90.Nilsson, I.M. Impaired fibrinolysis: new evidence in relation tothrombosis.
In: Jespersen J., Kluft C. and Korsgaard O. (edit). Clinical Aspects ofFibrinolysis and Thrombolysis. / I.M.Nilsson, L Tengborn. // Esbjerg: South JutlandUniv. Press.- 1983.- P. 273-291.91.Nordt, TK. Augmentation of arterial endothelial cell expression of theplasminogen activator inhibitor type-1 (PAI-1) gene by proinsulin and insulin invivo. / TK Nordt, H Sawa, S Fujii [et al.]// J Mol Cell Cardiol.- 1998.- Vol 30(8).P. 1535–43.92.Peeters, A.
A Cardiovascular Life History – A life course analysis ofthe original Framingham Heart Study cohort. / A Peeters, AA Mamun, F Willekins,L. Bonneux// Eur Heart J.- 2002.- Vol. 23.- P. 458–66.93.Poort, SR. A common genetic variation in the 3'-untranslated regionof the prothrombin gene is associated with elevated plasma prothrombin levels andan increase in venous thrombosis. / SR Poort, FR Rosendaal, PH Reitsma, RMBertina.// Blood.- 1996.- Vol.
88.- P. 3698-3703.9294.Prins, MH. A critical review of the evidence supporting a relationshipbetween impaired fibrinolytic activity and venous thromboembolism. / MH Prins, J.Hirsh// Arch Intern Med.- 1991. Vol. 151(9).- P. 1721–31.95.Qaseem, A. Clinical Guidelines Committee of the American Collegeof Physicians. Venous thromboembolism prophylaxis in hospitalized patients: aclinical practice guideline from the American College of Physicians. / A Qaseem, RChou, LL Humphrey [et al.]// Ann Intern Med.- 2011.- Vol.
155(9).- P. 625-32.96.Rabelink, T.J. Thrombosis and hemostasis in renal desease. /T.J.Rabelink, J.J.Zwaginga, H.A.Koomans [et al.]// Kidney Int.- 1994.-Vol. 46.- P.287–298.97.Rallidis, L.S.Plasminogen activator inhibitor 1 is elevated in thechildren of men with premature myocardial infarction. / L.S. Rallidis, A.A.Megalou, N.H. Papageorgakis [et al.]// Thromb. Haemost.- 1996.- Vol. 76.- P. 417–421.98.Ramsey, Sabi.
The Effects of Hypoxia on Markers of Coagulation andSystemic Infl ammation in Patients With COPD. / Sabi Ramsey, Thomas Paul, J.Shal Dennis [et al.]// Chest.- 2010. Vol. 138.- P. 47-51.99.Rani, M M. Fibrinolytic activity in coronary heart disease. / M M Rani,K K Nath, T N Mehrotra, S D Mishra.// J Postgrad Med.- 1981. Vol.
27.- P. 105.100.Reich, LM. Prospective study of subclinical atherosclerosis as a riskfactor for venous thromboembolism./ LM Reich, AR Folsom, NS Key [et al.] JThromb Haemost.- 2006.- Vol. Sep;4(9). -P. 1909-13.101.Ridker, PM. Circadian variation of acute myocardial infarction and theeffect of low-dose aspirin in a randomized trial of physicians.
/ PM Ridker, JEManson, JE Buring [et al.]// Circulation.- 1990.- Vol. 82(3).- P. 897–902.93102.Ringelstein, M. Promotor polymorphisms of plasminogen activatorinhibitor-1 and other thrombophilic genotypes in cerebral venous thrombosis: acase–control study in adults. / M Ringelstein, A Jung, K Berger [el al.]// J Neurol inpress.- http://dx.doi.org/10.1007/s00415-012-6477-7.103.Rizkallah, Jacques. Prevalence of Pulmonary Embolism in AcuteExacerbations of COPD.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
